Effect Of Photodynamic Therapy With1/3-dose Verteporfin For Central Serous Chorioretinopathy

Objective:To observe the effect of Photodynamic therapy (PDT) with1/3-doses verteporfin for central serous retinopathy.Methods:Chose CSC patients with lesions located in Macular foveal diagnosed by OCT and FFA, divided into two groups, A and B. A with Oral drug therapy,18eyes were enrolled.B treated using PDT with1/3-dose verteporfin,31eyes were enrolled. BCVA and OCT and Amsler Grid was performed before and at1week and1month and3months and6month after PDT. The macular retinal thickness, and the subretina] fluid volume were evaluated. All the results are used SPSS17.0of statistical analysis, P <0.05said differences with a statistical significance.Results:The total effectiveness in A group was94.4%, compared with the B group was70.9%,83.3%eyes had improved effects, compared with the B group was58.1%, the difference between the two groups the was statistically significant (p>0.05). The average best corrected visual acuity (BCVA) was improved from0.52to0.88in A group, compared with the B group was from0.54to0.70. The average course of treatment in A group was3.8weeks, compared with the B group was14.4weeks. Amsler Grid, FFA, OCT center retinal thickness and volume, in two groups were obviously improved, the difference was statistically significant (P<0.05),Conclusion:Photodynamic therapy with1/3-dose verteporfin appears to be an effective and safe treatment for patients with chorioretinopathy, and should be further popularized.